Core Viewpoint - The company plans to cancel a total of 202,230 shares repurchased in 2022, which accounts for 0.37% of the total share capital [1] Group 1 - The plan has been approved by the board of directors and the supervisory board, pending approval from the shareholders' meeting [1] - The repurchased shares were initially intended for employee stock incentive plans, but due to the expiration of the retention period, the purpose has been changed to cancellation and reduction of registered capital [1] - This action is not expected to have a substantial impact on the company's financial condition and operating results [1]

股票代码：300363 股票简称：博腾股份 公告编号：2025-045 号 重庆博腾制药科技股份有限公司 关于变更部分回购股份用途并注销的公告 公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 重庆博腾制药科技股份有限公司（以下简称"公司"）于 2025 年 8 月 21 日召开第六届董事会第三次会议、第六届监事会第二次会议，审议通过《关于变 更部分回购股份用途并注销的议案》，拟对公司于 2022 年 8 月 4 日召开的第五 届董事会第六次临时会议审议通过的《关于以集中竞价交易方式回购股份的议案》 的回购股份（以下简称"2022 年回购"）用途进行变更，由"用于实施股权激 励或员工持股计划"变更为"用于注销并减少公司注册资本"，并将对 2022 年 回购的全部股份，共计 2,022,344 股，予以注销。本事项尚需提交公司股东会审 议。具体情况如下： 一、回购情况概述 2022 年 8 月 4 日，公司召开第五届董事会第六次临时会议，审议通过《关 于以集中竞价交易方式回购股份的议案》，同意公司自董事会审议通过回购股份 方案之日起 12 个月内，以不低于人民币 5 ...

Group 1 - Boten Pharmaceutical Technology Co., Ltd. (stock code: 300363) provides comprehensive services for small molecule drugs, peptides, oligonucleotide drugs, proteins, conjugated drugs, and cell and gene therapies throughout the drug lifecycle, covering locations in China and several countries in Europe and the US [1] - The company has experienced a decline in stock price, with a cumulative drop of -3.44% over four consecutive trading days as of August 21 [1] - In the second quarter of this year, China Europe Fund's China Europe Medical Health Mixed A Fund entered the top ten shareholders of Boten Pharmaceutical, marking a new investment [1] Group 2 - The China Europe Medical Health Mixed A Fund has achieved a year-to-date return of 26.29%, ranking 1357 out of 4492 in its category [1] - The fund is managed by Guo Lan and Zhao Lei, both of whom have extensive backgrounds in biomedical engineering and finance [2][5] - Guo Lan has been with China Europe Fund since October 2014 and has managed multiple funds, while Zhao Lei joined in May 2021 and currently serves as the fund manager and head of the equity research team [4][5]

Core Viewpoint - The company has been deeply engaged in the CDMO industry for twenty years, providing services to global innovative pharmaceutical companies and accumulating rich experience and capabilities in research and development technology, delivery, and lean operations [1] Group 1: Company Overview - The company has established research and development teams in China, the United States, and Europe, collaboratively building a technology platform [1] - The company offers customized research and development services for various types of drugs, including small molecules, peptides, oligonucleotides, proteins and conjugates, and gene cell therapies [1] - The company supports hundreds of different types of research and development projects each year, assisting clients from IND application to the entire lifecycle until market launch [1]

证券日报网讯博腾股份（300363）8月19日在互动平台回答投资者提问时表示，截至2025年8月8日收 盘，公司股东总户数(合并普通账户和融资融券信用账户)为51513户。 ...

股票代码：300363 股票简称：博腾股份 公告编号：2025-040 号 重庆博腾制药科技股份有限公司 关于 2023 年员工持股计划提前终止的公告 公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、2023 年员工持股计划基本情况 重庆博腾制药科技股份有限公司（以下简称"公司"）于 2023 年 10 月 16 日 召开第五届董事会第二十次临时会议及第五届监事会第十五次临时会议，于 年员工持股计划（草案）>及其摘要的议案》 二、2023 年员工持股计划提前终止的情况 公司在实施本持股计划期间，严格遵守市场交易规则，遵守中国证监会、深 圳证券交易所关于敏感期不得买卖股票的规定，未利用任何内幕信息进行交易。 截至本公告披露日，本持股计划已在锁定期届满后的存续期内全部出售完毕， 且本持股计划项下货币资产已完成清算、分配工作。根据公司《2023 年员工持股 计划（草案）》的相关规定，经管理委员会同意，本持股计划提前终止，后续公 司将按照相关法律法规及本持股计划的规定推进终止后的相关工作。 特此公告。 重庆博腾制药科技股份有限公司董事会 根据《2023 年员工持股计 ...

重庆博腾制药科技股份有限公司 关于 2023 年员工持股计划提前终止的公告 公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、2023 年员工持股计划基本情况 重庆博腾制药科技股份有限公司（以下简称"公司"）于 2023 年 10 月 16 日 召开第五届董事会第二十次临时会议及第五届监事会第十五次临时会议，于 2023 年 11 月 1 日召开 2023 年第四次临时股东大会，审议通过《关于公司<2023 年员工持股计划（草案）>及其摘要的议案》《关于公司<2023 年员工持股计划管 理办法>的议案》《关于提请股东大会授权董事会办理公司 2023 年员工持股计划 相关事宜的议案》，同意公司实施 2023 年员工持股计划（以下简称"本持股计 划"）并授权董事会办理相关事宜。2024 年 2 月 27 日，公司完成本持股计划标 的股票购买。具体内容详见公司分别于 2023 年 10 月 17 日、2023 年 11 月 1 日、 2024 年 2 月 27 日在巨潮资讯网（www.cninfo.com.cn）披露的相关公告。 本持股计划的锁定期已于 2025 年 ...

Market Performance - On August 13, the medical services sector rose by 4.02%, led by Innovative Medical [1] - The Shanghai Composite Index closed at 3683.46, up 0.48%, while the Shenzhen Component Index closed at 11551.36, up 1.76% [1] Individual Stock Performance - The table lists various stocks in the medical services sector, with notable declines including *ST Bio down 4.95% and ST Zhongzhu down 2.66% [1] - Other stocks such as Lanwei Medical and Baicheng Pharmaceutical also experienced minor declines of 1.76% and 1.59% respectively [1] Capital Flow Analysis - The medical services sector saw a net inflow of 1.962 billion yuan from institutional investors, while retail investors experienced a net outflow of 1.888 billion yuan [3] - Notable stocks with significant net inflows from institutional investors include Yaoming Kande with 1.13 billion yuan and Kanglong Huacheng with 248 million yuan [3] - Conversely, retail investors showed significant outflows from stocks like Yaoming Kande and Kanglong Huacheng, indicating a shift in investor sentiment [3]

金融界消息 截至2025年8月12日收盘，博腾股份（300363）报收于22.45元，下跌1.79%，换手率 3.83%，成交量19.19万手，成交金额4.30亿元。 资金流向方面，今日主力资金净流出3311.86万元，占比成交额7.7%。其中，超大单净流出2637.96万 元、占成交额6.13%，大单净流出673.90万元、占成交额1.57%，中单净流出流入2995.24万元、占成交 额6.96%，小单净流入316.62万元、占成交额0.74%。 天眼查商业履历信息显示，重庆博腾制药科技股份有限公司，成立于2005年，位于重庆市，是一家以从 事医药制造业为主的企业。企业注册资本54546.452万人民币，实缴资本54546.452万人民币。公司法定 代表人为居年丰。 通过天眼查大数据分析，重庆博腾制药科技股份有限公司共对外投资了18家企业，参与招投标项目66 次，知识产权方面有商标信息193条，专利信息74条，此外企业还拥有行政许可252个。 来源：金融界 博腾股份最新一期业绩显示，截至2025一季报，公司营业总收入8.01亿元、同比增长18.21%，归属净利 润428.42万元，同比增长95.48%，扣非 ...

Group 1 - The stock price of Boteng Co., Ltd. closed at 23.68 yuan on August 5, 2025, down by 0.10 yuan, a decrease of 0.42% from the previous trading day [1] - The trading volume on that day reached 5.53 billion yuan, with a turnover rate of 4.65% [1] - A rapid rebound occurred at 1 PM, with a price increase of over 2% within 5 minutes, peaking at 24.18 yuan [1] Group 2 - Boteng Co., Ltd. operates in the chemical pharmaceutical industry, focusing on custom research and development production services for pharmaceuticals [1] - The company is registered in Chongqing and is involved in areas such as weight loss drugs and CAR-T cell therapy [1] - On August 5, the net outflow of main funds was 18.52 million yuan, with a cumulative net outflow of 318 million yuan over the past five days [1]